GAPDH and hepatocellular carcinoma: First report indicating 3-BrPA binding with GAPDHFirst loco-regional therapy demonstrating anticancer efficacy of 3-BrPAFirst biochemical evidence in human HCC cells indicating that GAPDH and could be the primary target of 3-BrPAFirst autoradiographic evidence in human HCC cells demonstrating GAPDH as the primary target of 3-BrPAFirst report demonstrating percutaneous ablation of human HCC by targeting GAPDH through 3-BrPA